Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: A boot code may be segmented to allow separate and independent storage of the code segments in a manner that may enable secure system boot by autonomous fetching and assembling of the boot code by a security sub-system. The code fetching may need to be done without the main CPU running on the chip for security reasons. Because the boot code may be stored in memory devices that require special software application to account for non-contiguous storage of data and/or code, for example a NAND flash memory which would require such an application as Bad Block Management, code segments stored in areas guaranteed to be usable may enable loading remaining segment separately and independently. Each of the code segments may be validated, wherein validation of the code segments may comprise use of hardware-based signatures.

Abstract: In multimedia systems requiring secure access, a method and apparatus for constructing an access control matrix for a set-top box security processor are provided. A security processor may comprise multiple security components and may support multiple user modes. For each user mode supported, at least one access rule table may be generated to indicate access rules to a security component in the security processor. An access control list comprises information regarding the access rules for a particular user mode to the security components in the security processor. An access control matrix may be generated based on the access control lists for the user modes supported by the security component. The access control matrix may be implemented and/or stored in the security processor for verifying access rights of a user mode. Results of operations associated with security components may be transferred to other processors communicatively coupled to the security processor.

Abstract: Segmenting a boot code to allow separate and independent storage and validation of the segments in a manner that enable secure system boot by autonomous fetching and assembling of the boot code by a security sub-system. The code fetching may need to be done without the main CPU running on the chip for security reasons. Because the boot code may be stored in memory devices that require special software application to account for non-contiguous storage of data and/or code, for example a NAND flash memory which would require such an application as Bad Block Management, code segments stored in areas guaranteed to be usable may enable loading and validating remaining segment separately and independently.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: In multimedia systems requiring secure access, a method and apparatus for constructing an access control matrix for a set-top box security processor are provided. A security processor may comprise multiple security components and may support multiple user modes. For each user mode supported, at least one access rule table may be generated to indicate access rules to a security component in the security processor. An access control list comprises information regarding the access rules for a particular user mode to the security components in the security processor. An access control matrix may be generated based on the access control lists for the user modes supported by the security component. The access control matrix may be implemented and/or stored in the security processor for verifying access rights of a user mode.

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are delivery devices for use in the treatment of otic disorders wherein the delivery device is administered locally to an individual afflicted with an otic disorder, through direct application or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with ion channel modulators. In these methods, the ion channel modulator compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the ion channel modulator compositions and formulations onto the auris interna target areas, or via perfusion into the auris interna structures.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with aural pressure modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).